New Hope in Fight Against the Flu
A multi-national consortium develops new approaches to cure the flu
Pharmacelsus will contribute its in vitro ADMET and in vivo pharmacokinetics expertise through sophisticated safety tests and by screening several drug candidates for beneficial pharmacological properties. The project started in October 2010 and runs for 4 years with almost €6 million in funding provided by the EU.
The FLUCURE project aims at developing innovative, first-in-class therapeutics against influenza by targeting its replication machinery. Small molecule inhibitors will be designed that interfere with virus-specific protein-protein interactions ultimately avoiding viral replication and spread. A consortium of 10 European partners will bring their expertise together to deliver several drug candidates suitable for clinical development.
Pharmacelsus GmbH is a GLP certified contract research organisation performing in vitro ADMET and in vivo PK services for drug discovery and development. Furthermore, Pharmacelsus provides bioanalytical support for clinical studies.